{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:36:08Z","timestamp":1769157368358,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The benefit of combining aspirin and direct oral anticoagulants on the reduction of cardiovascular events in atrial fibrillation or flutter is not well studied. We aimed to assess whether concurrent aspirin and direct oral anticoagulant therapy for atrial fibrillation or flutter will result in less coronary, cerebrovascular and systemic ischemic events compared to direct oral anticoagulant therapy alone.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Retrospective study of adult patients between 18 and 100\u2009years old who have nonvalvular atrial fibrillation or flutter and were started on a direct oral anticoagulant (apixaban, rivaroxaban, or dabigatran), between January 1, 2010 and September 1, 2015 within the Beaumont Health System. Exclusions were history of venous thromboembolic disease and use of other antiplatelet therapies such as P2Y12 inhibitors. Patients were classified into two groups based on concurrent aspirin use and observed for a minimum of 2 years. Primary outcome was major adverse cardiac events, defined as acute coronary syndromes, ischemic strokes, and embolic events. Secondary outcomes were bleeding and death.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Six thousand four patients were in the final analysis, 57% males and 80% Caucasians, median age 71, interquartile range (63\u201380). The group exposed to aspirin contained 2908 subjects, and the group unexposed to aspirin contained 3096 subjects. After using propensity scores to balance the baseline characteristics in both groups, the analysis revealed higher rate of major adverse cardiac events in the exposed group compared to the unexposed group, (HR 2.11, 95% CI (1.74\u20132.56)) with a number needed to harm of 11 (95% CI [9\u201311]). The rate of bleeding was also higher in the exposed group, (HR 1.30, 95% CI (1.11\u20131.52)). The rate of death was not statistically different between the groups, (HR 0.87, 95% CI (0.61\u20131.25)).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this observational analysis of patients with atrial fibrillation and flutter, the concomitant use of direct oral anticoagulants and aspirin was associated with an increased risk of both major adverse cardiac and bleeding events when compared to the use of direct oral anticoagulants alone. These findings underscore the potential harm of this combination therapy when used without a clear indication.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12872-020-01509-x","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T14:53:56Z","timestamp":1591196036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2629-592X","authenticated-orcid":false,"given":"Ahmad","family":"Said","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Keeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsel","family":"Matka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Hafeez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Halalau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"issue":"18","key":"1509_CR1","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370\u20135.","journal-title":"JAMA."},{"issue":"7","key":"1509_CR2","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/S0735-1097(00)00982-7","volume":"36","author":"J Granada","year":"2000","unstructured":"Granada J, Uribe W, Chyou PH, Maassen K, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36(7):2242.","journal-title":"J Am Coll Cardiol"},{"key":"1509_CR3","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D\u2019Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation. 1998;98:946\u201352.","journal-title":"Circulation"},{"issue":"7","key":"1509_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.113.002927","volume":"128","author":"BA Steinberg","year":"2013","unstructured":"Steinberg BA, Kim S, Piccini JP, et al. Use and associated risks of concomitant aspirin therapy with Oral anticoagulation in patients with atrial fibrillation insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry. Circulation. 2013;128(7):721\u20138.","journal-title":"Circulation."},{"issue":"23","key":"1509_CR5","first-page":"e199","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199\u2013267.","journal-title":"Circulation."},{"key":"1509_CR6","doi-asserted-by":"crossref","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Heart Rhythm 2019.","DOI":"10.1161\/CIR.0000000000000665"},{"key":"1509_CR7","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirschhof","year":"2016","unstructured":"Kirschhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"1509_CR8","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","volume":"127","author":"AL Dans","year":"2013","unstructured":"Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2013;127:634\u201340.","journal-title":"Circulation"},{"key":"1509_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1160\/TH11-05-0364","volume":"106","author":"JB Olesen","year":"2011","unstructured":"Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a \u2018real world\u2019 nationwide cohort study. Thromb Haemost. 2011;106:739\u201349.","journal-title":"Thromb Haemost"},{"key":"1509_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/CRD.0000000000000088","volume":"24","author":"S Kumar","year":"2016","unstructured":"Kumar S, Danik SB, Altman RK, et al. Non-vitamin\u2002K\u2002antagonist\u2002oral\u2002anticoagulants\u2002and\u2002a therapy\u2002for\u2002stroke\u2002prevention\u2002in\u2002patients\u2002with\u2002atrial: a meta-analysis of randomized controlled trials. Cardiol Rev. 2016;24:218\u201323.","journal-title":"Cardiol Rev"},{"issue":"10","key":"1509_CR11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/clc.22750","volume":"40","author":"G Lemesle","year":"2017","unstructured":"Lemesle G, Ducrocq G, Elbez Y, et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: association with ischemic and bleeding events. Clin Cardiol. 2017;40(10):932\u20139. https:\/\/doi.org\/10.1002\/clc.22750.","journal-title":"Clin Cardiol"},{"key":"1509_CR12","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140:e596\u2013646.","journal-title":"Circulation."},{"issue":"23","key":"1509_CR13","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","volume":"73","author":"HK Abdelaziz","year":"2019","unstructured":"Abdelaziz HK, Saad M, Pothineni NVK, et al. Aspirin for primary prevention of cardiovascular events. J Am Coll Cardiol. 2019;73(23):2915\u201329.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1509_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","volume":"321","author":"SL Zheng","year":"2019","unstructured":"Zheng SL, Roddick AJ. Association of Aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321(3):277\u201387.","journal-title":"JAMA."}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01509-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-020-01509-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01509-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T23:36:25Z","timestamp":1622504185000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01509-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01509-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Beaumont Health System Institutional Review Board (IRB). Beaumont Research Institute granted the authors permission to access the data used in our study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}